関連する実験動画
Updated: Jun 23, 2026
14:19
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
B型ナトリウレチンペプチドとエジェクション分子は,心筋梗塞後の予後のために使用されます
A Mark Richards1, M Gary Nicholls, Eric A Espiner
1Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand. mark.richards@cdhb.govt.nz
Circulation
|May 29, 2003
まとめ
血B型ナトリウレチンペプチド (BNP) と左心室噴出分数 (LVEF) は,心筋梗塞後の有害事象の主要な予測因子である. BNPとLVEFの組み合わせは,患者のアウトカムを改善するための優れたリスクの階層化を提供します.
科学分野:
- 心臓病学 心臓病学
- バイオマーカー バイオマーカー
- 予測指標 予測指標
背景:
- 血B型ナトリウレチンペプチド (BNP) は,急性冠動脈症候群における死亡率,心不全,心筋梗塞を独立して予測します.
- 左心室噴出分数 (LVEF) は,急性心損傷後の予後と治療反応において極めて重要です.
研究 の 目的:
- BNP,アミノ端末BNP (N-BNP),ノルエピネフリン,および放射性核酸LVEFの同時測定の予後的有用性を,急性心筋梗塞患者の大きなコホートで評価する.
- 組合せられたBNP/N-BNPとLVEFの測定が個々のマーカーと比較してリスクの階層化を改善するかどうかを判断する.
主な方法:
- 急性心筋梗塞の666人の患者のコホートの分析.
- 血BNP,N-BNP,ノレピネフリン,放射性核酸LVEFの同時測定.
- 独立した予測値と,リスク層分化の有効性を評価するための統計分析.
主要な成果:
- B型ペプチド (BNP,N-BNP) とLVEFは,それぞれ独立して死亡,心不全,新発心筋梗塞 (P<0.001) を予測した.
- 組み合わせたBNP/N-BNPとLVEFは,個々のマーカーを超えてリスクの階層化を大幅に改善しました.
- 増加したN-BNP/BNPは,特にLVEF <40%の患者で新しい心筋梗塞を予測しました.
結論:
- プラズマのN-BNP (またはBNP) とLVEFは,心筋梗塞後の主要な有害事象の補完的で独立した予測因子です.
- N-BNP/BNPとLVEFを組み合わせて測定すると,リスクの階層化は大幅に改善されます.
関連する概念動画
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...